QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
NASDAQ:GMAB

Genmab A/S - GMAB Price Target & Analyst Ratings

$38.87
+0.19 (+0.49%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$38.52
$39.04
50-Day Range
$38.68
$47.06
52-Week Range
$26.19
$47.50
Volume
578,332 shs
Average Volume
596,546 shs
Market Capitalization
$25.64 billion
P/E Ratio
31.86
Dividend Yield
N/A
Price Target
$38.55

Genmab A/S Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 15 Analyst Ratings

Consensus Analyst Price Target

$38.55
-0.83% Downside
High Prediction$51.00
Average Prediction$38.55
Low Prediction$31.00
TypeCurrent
1/27/22 to 1/27/23
1 Month Ago
12/28/21 to 12/28/22
3 Months Ago
10/29/21 to 10/29/22
1 Year Ago
1/27/21 to 1/27/22
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
2 Buy rating(s)
6 Buy rating(s)
Hold
10 Hold rating(s)
11 Hold rating(s)
8 Hold rating(s)
5 Hold rating(s)
Sell
2 Sell rating(s)
2 Sell rating(s)
1 Sell rating(s)
3 Sell rating(s)
Consensus Price Target$38.55$38.55$37.15$46.00
Predicted Upside-0.83% Downside3.06% Upside6.20% Upside4.32% Upside
Get Genmab A/S Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for GMAB and its competitors with MarketBeat's FREE daily newsletter.


GMAB Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GMAB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Genmab A/S Stock vs. The Competition

TypeGenmab A/SMedical CompaniesS&P 500
Consensus Rating Score
2.07
2.64
2.46
Consensus RatingHoldBuyHold
Predicted Upside-0.35% Downside1,311.54% Upside10.06% Upside
News Sentiment RatingPositive News
Positive News
Neutral News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
1/3/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight3,450.00 ➝ 3,600.00
12/20/2022Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
11/17/2022AlphaValue
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeReduce
11/15/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$43.00-0.23%
11/14/2022William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Phipps
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform
11/11/2022Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
11/10/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform$33.00-20.06%
10/17/2022DNB Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
8/22/2022HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Ram Selvaraju
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy$49.00 ➝ $51.00+42.10%
8/15/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetUnderweight$29.00 ➝ $31.00-16.24%
6/23/2022BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform$34.73+11.64%
5/13/2022Bryan, Garnier & Co
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Victor Floch
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSell ➝ Neutral
5/13/2022Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeSell ➝ Hold
3/16/2022UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy
1/3/2022Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
9/16/2021Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$45.50 ➝ $48.00+11.99%
8/16/2021Societe Generale
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingSell
8/12/2021Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight
8/12/2021Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$46.00 ➝ $55.00+19.67%
2/25/2021Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$42.00 ➝ $47.00+38.72%
2/24/2021Danske
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
10/27/2020The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral$37.00+5.80%
6/25/2020Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Neutral
6/11/2020SunTrust Banks
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$36.00 ➝ $39.00+29.05%
(Data available from 1/27/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












GMAB Price Target - Frequently Asked Questions

What is Genmab A/S's consensus rating and price target?

According to the issued ratings of 15 analysts in the last year, the consensus rating for Genmab A/S stock is Hold based on the current 2 sell ratings, 10 hold ratings and 3 buy ratings for GMAB. The average twelve-month price prediction for Genmab A/S is $38.55 with a high price target of $51.00 and a low price target of $31.00. Learn more on GMAB's analyst rating history.

Do Wall Street analysts like Genmab A/S more than its competitors?

Analysts like Genmab A/S less than other Medical companies. The consensus rating for Genmab A/S is Hold while the average consensus rating for medical companies is Buy. Learn more on how GMAB compares to other companies.

Is Genmab A/S being upgraded or downgraded by Wall Street analysts?

Over the previous 90 days, Genmab A/S's stock had 2 downgrades and 1 upgrade by analysts.

Does Genmab A/S's stock price have much upside?

According to analysts, Genmab A/S's stock has a predicted upside of 2.94% based on their 12-month price targets.

What analysts cover Genmab A/S?

Genmab A/S has been rated by AlphaValue, Citigroup, Cowen, Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., SVB Leerink, and William Blair in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:GMAB) was last updated on 1/27/2023 by MarketBeat.com Staff